An Albumin Sandwich Enhances in Vivo Circulation and Stability of Metabolically Labile Peptides
Rui Tian,Shoujun Zhu,Qiao Zeng,Lixin Lang,Ying Ma,Dale O Kiesewetter,Yi Liu,Xiao Fu,Joseph Lau,Guizhi Zhu,Orit Jacobson,Zhantong Wang,Yunlu Dai,Guocan Yu,Bernard R Brooks,Gang Liu,Gang Niu,Xiaoyuan Chen
DOI: https://doi.org/10.1021/acs.bioconjchem.9b00258
2019-06-19
Abstract:The effectiveness of numerous molecular drugs is hampered by their poor pharmacokinetics. Different from previous approaches with limited effectiveness, most recently, emerging high-affinity albumin binding moieties (ABMs) for in vivo hitchhiking of endogenous albumin opens up an avenue to chaperone small molecules for long-acting therapeutics. Although several FDA-approved fatty acids have shown prolonged residence and therapeutic effect, an easily synthesized, water-soluble, and high-efficiency ABM with versatile drug loading ability is urgently needed to improve the therapeutic efficacy of short-lived constructs. We herein identified an ideal bivalent Evans blue derivative, denoted as N(tEB)2, as a smart ABM-delivery platform to chaperone short-lived molecules, through both computational modeling screening and efficient synthetic schemes. The optimal N(tEB)2 could reversibly link two molecules of albumin through its two binding heads with a preferable spacer, resulting in significantly extended circulation half-life of a preloaded cargo and water-soluble. Notably, this in situ dimerization of albumin was able to sandwich peptide therapeutics to protect them from proteolysis. As an application, we conjugated N(tEB)2 with exendin-4 for long-acting glucose control in a diabetic mouse model, and it was superior to both previously tested NtEB-exendin-4 (Abextide) and the newly FDA-approved semaglutide, which has been arguably the best commercial weekly formula so far. Hence, this novel albumin binder has excellent clinical potential for next-generation biomimetic drug delivery systems.